{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigyy3rdllfefyexeg32tgmepeiixgenfamts7icocprvlp7ioscv4",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mgwxhyj7h3b2"
  },
  "path": "/2026/03/13/unixell-biotech-receives-ind-clearance-by-fda-for-its-allogeneic-ipsc-derived-cell-therapy-ux-gip001-for-focal-epilepsy/",
  "publishedAt": "2026-03-13T12:06:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SHANGHAI, March 13, 2026 /PRNewswire/ — On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This breakthrough marks UX-GIP001 as the first iPSC-derived allogeneic epilepsy cell therapy approved in the U.S. and […]",
  "title": "Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy"
}